Welcome to our dedicated page for Regeneron Pharmaceuticals SEC filings (Ticker: REGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a publicly traded biotechnology company incorporated in New York, Regeneron files a range of documents that detail its financial performance, risk factors, material events and governance.
Among the most frequently referenced filings are current reports on Form 8‑K, which Regeneron uses to furnish press releases announcing quarterly and annual financial and operating results. For example, the company has filed Forms 8‑K to report results for quarters ended June 30, 2025 and September 30, 2025, and to describe specific items such as acquired in‑process research and development charges related to collaboration agreements. These filings help investors understand how licensing deals, development milestones and other events affect reported earnings.
In addition to 8‑K reports, investors typically review annual reports on Form 10‑K and quarterly reports on Form 10‑Q for a comprehensive view of Regeneron’s business. These documents generally include information on its portfolio of medicines and product candidates, collaboration structures with partners such as Sanofi, Bayer, Alnylam and Tessera Therapeutics, and descriptions of proprietary platforms like VelocImmune and VelociSuite. They also outline key risks related to clinical development, regulatory approvals, manufacturing, competition and reimbursement.
Stock Titan enhances access to Regeneron’s filings by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. AI-generated overviews can help explain complex sections of lengthy 10‑K and 10‑Q reports, highlight notable items in 8‑K disclosures and clarify technical language around non‑GAAP financial measures or collaboration accounting. Users can also review insider transaction reports on Form 4, proxy statements on Schedule 14A and other documents relevant to governance and executive compensation.
By using this page, investors, analysts and researchers can quickly locate and interpret Regeneron’s official SEC filings, while AI tools assist in identifying the portions most relevant to financial performance, pipeline progress and material corporate events.
Regeneron Pharmaceuticals director Michael S. Brown reported new equity awards. On January 2, 2026, he received 155 time-based restricted stock units, each representing one share of Regeneron common stock, bringing his directly held common stock to 1,703 shares. He was also granted a non-qualified stock option for 1,962 shares with an exercise price of $772.76 per share, expiring on January 2, 2036; a portion becomes exercisable on the date of the first annual shareholder meeting after the grant, with the remainder on the first anniversary of the grant date.
In addition, the filing lists 5,000 shares held indirectly by a SLAT and 6,162 shares held indirectly by a trust. The trust is for the benefit of Brown’s immediate family, his spouse is trustee, and he disclaims beneficial ownership of those trust-held securities.
Regeneron Pharmaceuticals, Inc. reported an insider stock transaction by executive Daniel P. Van Plew, EVP & General Mgr, Industrial.
On 12/09/2025, he reported a transaction coded F involving the disposition of 2,552 shares of common stock at $701.51 per share. After this, he reported beneficial ownership of 21,673 shares held directly, 12,376 shares held indirectly through a 2025 GRAT, and 1,129 shares held through a 401(k) plan.
Regeneron Pharmaceuticals, Inc. reported an insider stock transaction by an officer serving as EVP Research. On 12/09/2025, the executive disposed of 4,229 shares of common stock at $701.51 per share in a transaction coded "F".
Following this activity, the officer beneficially owned 47,833 shares of Regeneron common stock directly and 4,375 shares indirectly through a 401(k) plan.
Regeneron Pharmaceuticals’ VP Controller reported new equity awards and related share movements. On December 5, 2025, the officer received 2,064 shares of common stock at $0.0 per share as restricted stock under the Second Amended and Restated 2014 Long-Term Incentive Plan, vesting 50% on December 5, 2027 and 50% on December 5, 2029. The same day, the officer was granted a non-qualified stock option for 2,261 shares of common stock with an exercise price of $726.71 per share, expiring on December 5, 2035 and vesting in four equal annual installments beginning one year after the grant date.
On December 8, 2025, the filing shows a disposition of 989 shares of common stock at $712.94 per share. Following these transactions, the officer directly owns 5,308 common shares, with additional indirect holdings of 31 shares through a 401(k) plan and 179 shares held by a spouse, along with the 2,261 stock options.
Regeneron Pharmaceuticals (REGN) executive Joseph LaRosa reported a stock option exercise and share transactions. On 11/20/2025, he exercised a non-qualified stock option for 14,450 shares of common stock at an exercise price of $555.67 per share. On the same date, 12,686 shares were disposed of in a transaction reported at $736.77 per share, which is typically associated with covering taxes or similar obligations.
Following these transactions, LaRosa directly beneficially owned 22,839 shares of Regeneron common stock. He also indirectly owned 9,000 shares through a 2024 GRAT, 9,000 shares through a 2025 GRAT, and 395 shares through a 401(k) plan. The option award referenced in the filing vested in four equal annual installments starting one year after the grant date and is now fully exercised, with zero derivative securities remaining from this grant.
Regeneron Pharmaceuticals (REGN) director reports stock option exercise and sale. On 11/20/2025, the reporting person exercised a non-qualified stock option for 760 shares of common stock at an exercise price of $371.4 per share and then sold 760 shares of common stock at a price of $750 per share. After these transactions, the director beneficially owned 1,548 shares of Regeneron common stock directly and 756 non-qualified stock options. The transactions were made under a Rule 10b5-1(c) trading plan adopted on May 2, 2025.
Regeneron Pharmaceuticals (REGN) reported an insider transaction on Form 4. The company’s VP Controller sold 431 shares of common stock at $651.43 per share on 11/07/2025 (transaction code S). Following the sale, the reporting person beneficially owns 4,233 shares directly, plus 31 shares held by a 401(k) plan and 179 shares held by a trust. This filing documents a routine change in personal holdings and does not alter the company’s capital structure.
REGENERON PHARMACEUTICALS, INC. filed a Form 13F reporting institutional holdings totaling $700,444,832. The filing lists 4 information-table entries and was submitted as a 13F Holdings Report by the reporting manager. The report certifies the information is true and complete and is signed by Leonard Brooks, Senior Vice President, Treasurer.
Regeneron Pharmaceuticals (REGN) director Christine A. Poon reported insider transactions. On 10/29/2025, she exercised 6,500 non-qualified stock options at $520.01 and sold shares in multiple trades: 650 at $652.68, 2,735 at $653.5, 1,915 at $654.42, 100 at $655.1, 712 at $656.5, and 388 at $657.29.
On 10/30/2025, she exercised an additional 2,712 options at $520.01. Following the reported transactions, she beneficially owned 5,064 shares, held directly.
Regeneron Pharmaceuticals (REGN) executive Andrew Murphy reported insider transactions. On 10/29/2025, he exercised 35,000 non‑qualified stock options at $555.67 per share (code M), acquiring common stock. To cover taxes, 32,490 shares were withheld at $648.82 (code F). On 10/30/2025, he made a bona fide gift of 1,538 shares (code G).
After these transactions, he beneficially owned 50,046 shares directly and 4,370 shares indirectly via a 401(k) plan. The exercised option, which was scheduled to expire on 12/16/2025 and vested in four annual installments, now has 0 remaining.